Who we are

Synergus is a consulting company providing European market access and health economics services for medical device and in-vitro diagnostic companies and organisations

  • Synergus is a consulting company exclusively focused on medical devices and in-vitro diagnostics in Europe
  • Synergus offers a one-stop shop from market access strategy to hands-on execution
  • Synergus offers a full range of life-cycle support in clinical and economic evidence development
  • Our team consists of experienced market access consultants, medical doctors, analysts, researchers and statisticians
  • Synergus Analytics provides access to number of unique European market intelligence tools, including databases of health technology assessment decisions, procedure volume and DRG tariffs


Synergus provides support with development of all common types of value documentation (value summary, core value dossier and business case) and apps for value communication


Market Access

Our business is to help you find the most optimal way to establish the desired market uptake in your countries of target. In this process we can provide services throughout the life cycle, starting with the development of the market access strategy to the execution of either health economic evidence or changing the reimbursement system

read more

Health Economics

We provide full range of support in the area of health economics, including health economics modelling and incorporation of economic outcomes into clinical trials. Economic models can be published or presented in a user-friendly sales tools

read more

Evidence Generation

Synergus can provide support in analyzing evidence requirements for technology and contributing to evidence generation strategy. Strategy includes perspective of key stakeholders: reimbursement/HTA authorities, clinical societies, medical community and competitors

read more

Systematic Reviews

Synergus can provide support in developing and publishing results of state-of-art systematic literature reviews and meta-analysis

read more

Value Demonstration

Synergus provides support with development of all common types of value documentation (value summary, core value dossier and business case)

read more


Our services cover 15 European countries: Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland and the United Kingdom

read more


With Synergus Analytics we have started a journey to create insight in different data sets relating to healthcare. In our process we are combining manual analysis of data with a process of learning how to use smart technical solutions to extract data


HTA Update

Monthly customized e-mail alerts and online database of health technology assessment reports for medical devices and in-vitro diagnostics in Europe.

read more

Market Access Monitor

Bi-weekly newsletter about developments of reimbursement and funding landscape for medical devices and in-vitro diagnostics in Europe.

read more

Volume Data

Granular and specific information about annual volume of hospital procedures and diagnoses in major European countries.

read more

Reimbursement country overviews

Comprehensive overview of reimbursement systems in European countries in the report format. 

read more

Data Interface

Data can be delivered in different formats to be integrated within client’s IT infrastructure. 

read more



May 2016

We have recently reviewed the number of HTA reports regarding imaging modalities. We can see somewhat of a reduction during 2015 compared to 2014. The trend for the first 4 months of 2016 would indicate an increase compared to the year before. Subscribe to our HTA services to stay on top of what is happening: http://htasearch.synergus.com/

May 2016

There are many aspects that are changing with the introduction of the new 137h process to assess the benefit of the new innovations coming to market. We will provide more information about all of these changes in a webinar in a few weeks. 

May 2016

The German landscape for introduction of new technologies and drugs is changing dramatic. For drugs, the introduction of the Amnog process has been a drastic change. Now the medical devices are undergoing a similar drastic change, where new medical technologies coming to market through the innovation funding pathway have to go through a benefit assessment. 



May 2016

Our team has recently published the first comprehensive overview of the use of blood glucose monitoring in phase III clinical studies of insulin analogs, “

Apr 2016

We are happy to announce that Mikael Svensson will join us on part-time to strengthen our health economic expertize.

Mar 2016

The French Ministry of Social Affairs, Health and Women’s Rights introduced new possibilities of reimbursement for some invasive medical devices that could not find a proper registration place in the LPPR.

Get in Contact

Secure your market entry

Contact us Find us